Table 2.
Univariable regression analysis for cf-PWV
| Variables | Coefficient estimate (95% CI) | p-value |
|---|---|---|
| Time | −0.52 (−1.06; 0.02) | 0.057 |
| Age | 0.11 (0.04; 0.02) | 0.002 |
| BMI | 0.01 (−0.14; 0.17) | 0.899 |
| Smoking | −0.47 (−2.05; 1.11) | 0.561 |
| ESS | 0.13 (0.04; 0.23) | 0.004 |
| ESS >10 | −0.15 (−1.47; 1.17) | 0.822 |
| AHI (events/h) | 0.01 (−0.03; 0.04) | 0.725 |
| ODI (events/h) | 0.01 (−0.03; 0.04) | 0.705 |
| Mean SaO2 (%) | −0.06 (−0.37; 0.26) | 0.730 |
| Lower SaO2 (%) | 0.04 (−0.04; 0.11) | 0.366 |
| SaO2 < 90% (%) | −0.002 (−0.04; 0.03) | 0.917 |
| CPAP compliance | −0.09 (−0.67; 0.48) | 0.752 |
| Total cholesterol, mg/dl | −0.002 (−0.02; 0.02) | 0.794 |
| HDL-cholesterol, mg/dl | −0.05 (−0.10; 0.01) | 0.127 |
| LDL-cholesterol, mg/dl | −0.01 (−0.03; 0.01) | 0.554 |
| Triglycerides, mg/dl | 0.01 (−0.00; 0.02) | 0.168 |
| Glucose, mg/dl | 0.02 (−0.01; 0.05) | 0.229 |
| HbA1c, % | 0.41 (−0.076; 1.59) | 0.490 |
| 24 h SBP (mm Hg) | 0.09 (0.04; 0.14) | <0.001 |
| 24 h DBP (mm Hg) | 0.05 (−0.01; 0.12) | 0.109 |
| Pulse pressure (mm Hg) | 0.15 (0.08; 0.21) | <0.001 |
| 24 h MBP (mm Hg) | 0.04 (−0.02; 0.10) | 0.224 |
| Day-time SBP (mm Hg) | 0.09 (0.04; 0.13) | <0.001 |
| Day-time DBP (mm Hg) | 0.04 (0.02; 0.11) | 0.167 |
| Night-time SBP (mm Hg) | 0.07 (0.03; 0.11) | 0.002 |
| Night-time DBP (mm Hg) | 0.05 (−0.01; 0.11) | 0.109 |
| Hypertension | 1.29 (−0.24; 2.81) | 0.099 |
| Antihypertensive drugs | 1.37 (0.13; 2.61) | 0.030 |
| Dyslipidaemia | 0.49 (−1.19; 2.17) | 0.569 |
| Lipid lowering drugs | 0.22 (−1.09; 1.52) | 0.745 |
| MetS | 1.44 (0.18; 2.70) | 0.025 |
CPAP continuous positive airway treatment, BMI Body mass index, ESS Epworth Sleepiness Scale, AHI Apnea/Hypopnea Index, ODI Oxygen Desaturation Index, SaO 2 arterial oxygen saturation, HbA1c glycated haemoglobin, SBP systolic blood pressure, DBP diastolic blood pressure, MetS metabolic syndrome, cf-PWV carotid-femoral pulse wave velocity, p-values were obtained by linear mixed effects regression models